The estimated Net Worth of Nicholas Naclerio is at least $11.2 million dollars as of 21 March 2016. Nicholas Naclerio owns over 4,520 units of Illumina Inc stock worth over $3,747,397 and over the last 13 years Nicholas sold ILMN stock worth over $7,458,186.
Nicholas has made over 34 trades of the Illumina Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Nicholas sold 4,520 units of ILMN stock worth $697,210 on 21 March 2016.
The largest trade Nicholas's ever made was exercising 60,000 units of Illumina Inc stock on 2 June 2014 worth over $2,602,200. On average, Nicholas trades about 7,102 units every 23 days since 2012. As of 21 March 2016 Nicholas still owns at least 30,020 units of Illumina Inc stock.
You can see the complete history of Nicholas Naclerio stock trades at the bottom of the page.
Nicholas's mailing address filed with the SEC is 5200 ILLUMINA WAY, , SAN DIEGO, CA, 92122.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley et Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: